Shares of Cord Blood America (OTCBB: CBAI) slowly declined to a close of 2 cents this afternoon, a natural descent after shares spiked to 4 cents Monday morning. Shares began climbing last week when the company released testimony of a client that recently used Cord Blood’s umbilical cord blood storage.
“I have never experienced greater satisfaction than the gift of preserving my granddaughter’s cord blood stem cells,” Greg Smith, CEO of Mountain State Blue Cross Blue Shield, said in a statement. “The thought of possibly protecting Gracie from a serious disease long after I’m gone is an incredible feeling. I am hopeful many more MSBCBS customers will take advantage of the discount CorCell offers our members.”
Cord Blood is a parent company to CorCell; together the companies focus on stem cell preservation used to save lives through the extraction and storage of umbilical cord cells. CorCell’s mission is to become the most respected stem cell preservation company in the industry.
“Stem cells are used today in the treatment of various blood cancers including leukemia, lymphoma, and myelomas such as Hodgkin’s Disease and are used to treat benign blood diseases such as anemia and immune deficiency disorders,” Matthew Schissler, CEO of Cord Blood, stated. “Their potential use in fighting our most intractable diseases in the future, including diabetes and heart disease, is enormous. We can understand why Mr. Smith is so enthused over his gift of life.”
Cord blood stem cells are collected quickly, safely and non-invasively – harmless to both mother and child.
Let us hear your thoughts: Cord Blood America Inc. Message Board
